Patent · US Active

Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same

US8153616B2 · kind B2 · utility

0Cited by

23References

6Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Susan Zeun · Berlin, DE
Pol Boudes · Fremont, US
Angelo Secci · Parsippany-Troy Hills, US
Jan Nedrikat · Kirkland, CA
Holger Zimmermann · Falkensee, DE

Key dates

Filing date	Dec 12, 2006
Grant date	Apr 10, 2012
Priority date	—
Expiry date	Oct 27, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P15/18
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The multiphase combination preparation for oral therapy of dysfunctional uterine bleeding and for oral contraception contains a first phase consisting of 2 daily dosage units, each containing 3 mg of estradiol valerate or <3 mg of estradiol; a second phase consisting of a first group of 5 daily dosage units, each consisting of a combination of 2 mg of dienogest with 2 mg of estradiol valerate or <2 mg of estradiol, and a second group consisting of 17 daily dosage units, each consisting of a combination of 3 mg of dienogest with 2 mg of estradiol valerate or <2 mg of estradiol; a third phase consisting of 2 daily dosage units, each containing 1 mg of estradiol valerate or <1 mg of estradiol; and another phase consisting of 2 daily dosage units of a pharmaceutically harmless placebos.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.